Oral Semaglutide vs Injection: Pills, Pens, and What Actually Differs
Oral semaglutide (Rybelsus, Ozempic, Wegovy tablets) and injectable semaglutide (Ozempic, Wegovy) are the same molecule with different rules: pills are daily on an empty stomach with a 30-minute wait; shots are weekly with no food limits. OASIS 4: the 25 mg pill gave −13.6% weight loss vs −2.2% placebo.
Semaglutides.org provides information only, not medical advice. Talk to a licensed provider about your own care before making changes. Some telehealth links are affiliate links and are labeled where they appear.
Semaglutide is one molecule sold in the US under three brand names — Ozempic, Wegovy, and Rybelsus — and it now comes in both a once-weekly injection and a once-daily tablet [1][2][3]. The active drug is the same either way. What differs is how it gets into the body, what the FDA has approved it for, and the rules that come with each form. Injections go under the skin once a week at any time of day, with or without meals [2][3]. Tablets are swallowed once a day on an empty stomach in the morning with up to 4 ounces of water, and the label requires waiting at least 30 minutes before eating, drinking anything else, or taking other oral medicines [1][2].
Which form to ask a doctor about depends mostly on the condition being treated, whether a daily fasting routine fits, and whether the highest strengths matter. Tablet strengths are not interchangeable with injection strengths on a milligram basis [1], and some approved uses — for adolescents and for the liver condition MASH — are covered only by the injection [2].
What semaglutide products are available in the US?
All of the products are labeled by Novo Nordisk Pharmaceutical Industries, LP, and semaglutide’s initial US approval was in 2017 [1][2][3]. Here is how the lineup currently breaks down:
| Product | Form | Frequency | Strengths | Approved use |
|---|---|---|---|---|
| Ozempic | Injection under the skin | Once weekly | Pens: 2 mg/3 mL, 4 mg/3 mL, 8 mg/3 mL (doses of 0.25, 0.5, 1, or 2 mg weekly); also single-dose prefilled syringes: 0.25, 0.5, or 1 mg per 0.5 mL [3] | Type 2 diabetes [3] |
| Ozempic | Tablet | Once daily | 1.5 mg, 4 mg, 9 mg [1] | Type 2 diabetes [1] |
| Rybelsus | Tablet | Once daily | 3 mg, 7 mg, 14 mg [1] | Type 2 diabetes [1] |
| Wegovy | Injection under the skin | Once weekly | Pens: 0.25, 0.5, 1, 1.7, 2.4, 7.2 mg (Wegovy HD); syringes: 0.25–2.4 mg; FlexTouch pen: four 2.4 mg doses [2] | Weight management, cardiovascular risk, MASH [2] |
| Wegovy | Tablet | Once daily | 1.5 mg, 4 mg, 9 mg, 25 mg [2] | Weight management and cardiovascular risk in adults [2] |
Rybelsus and Ozempic tablets share one FDA label, which was updated January 30, 2026 [1]. The Ozempic injection label’s revision footer reads “Revised: 5/2026” [3], and the Wegovy label was updated June 18, 2026 [2].
What is the difference between Ozempic, Wegovy, and Rybelsus?
Same molecule, different approved uses and strength ladders. “Ozempic” now covers both a weekly injection and a daily tablet, with different dose schedules for each [1][3]. “Wegovy” covers both a weekly injection and a 25 mg daily tablet [2][4]. Rybelsus remains an approved, currently labeled oral semaglutide for type 2 diabetes [1].
Ozempic injection is approved to improve glycemic control in adults with type 2 diabetes, to reduce the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease, and to reduce the risk of sustained eGFR decline, end-stage kidney disease, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease [3]. Rybelsus and Ozempic tablets are approved for glycemic control in adults with type 2 diabetes and to reduce MACE risk in adults with type 2 diabetes at high risk for these events [1].
Wegovy injection is approved for MACE risk reduction in adults with established cardiovascular disease and either obesity or overweight; for weight reduction in adults and in patients aged 12 and older with obesity, or in adults with overweight plus at least one weight-related comorbidity; and for noncirrhotic MASH with F2–F3 fibrosis under accelerated approval [2]. Wegovy tablets are approved for MACE risk reduction and for weight reduction in adults only — no pediatric indication and no MASH indication [2]. Continued approval of the MASH indication may depend on verification of clinical benefit in a confirmatory trial [2].
One limitation of use applies across the brand: concomitant use of Wegovy tablets or injection with other semaglutide-containing products or any other GLP-1 receptor agonist is not recommended [2].
Why do you have to take Rybelsus on an empty stomach?
Because food can sharply reduce how much semaglutide the body absorbs. The label instructs patients to take Rybelsus or Ozempic tablets once daily on an empty stomach in the morning with water — up to 4 ounces of water, and no other liquids — to swallow the tablet whole without splitting, crushing, chewing, or dissolving it, and to wait at least 30 minutes before eating food, drinking beverages, or taking other oral medications [1][2].
Two pharmacokinetic trials back those rules. In a food-effect trial, 78 healthy subjects took oral semaglutide for 10 days; the fed arm, which ate a meal 30 minutes before dosing, had limited or no measurable semaglutide exposure, while every subject in the fasting arm had measurable exposure [8]. In the same trial, fasting from overnight until 4 hours after the dose produced AUC and maximum concentration that were numerically greater by approximately 40% than a reference arm that fasted only until 30 minutes after the dose — a difference that did not reach statistical significance (p=0.082 and p=0.080) [8].
A separate dosing-conditions trial in 161 healthy men found that 50 mL versus 120 mL of water gave comparable exposure (p=0.541 and p=0.676), but exposure increased with longer post-dose fasting up to 120 minutes (p<0.001), particularly between 15 and 30 minutes [8]. The researchers concluded that a fasting state, up to 120 mL of water, and at least 30 minutes of post-dose fasting produce clinically relevant exposure — the conditions used in the phase 3 trials and written into the approved label [8].
The injection has none of these restrictions: it is given once weekly at any time of day, with or without meals, into the abdomen, thigh, or upper arm [2][3].
What is SNAC in Rybelsus?
SNAC is the absorption enhancer that makes an oral peptide possible. Its full chemical name is sodium N-(8-[2-hydroxybenzoyl]amino) caprylate, also called salcaprozate sodium, and oral semaglutide tablets are co-formulated with it [7][8]. In regulatory assessment, SNAC is classified as an excipient and absorption enhancer [7].
The reason a helper is needed: swallowed peptide drugs are normally broken down by the stomach’s low pH and proteolytic enzymes, and they have poor permeability across the gastrointestinal epithelium [8]. Semaglutide itself is 94% structurally homologous to human GLP-1, modified to achieve a half-life of approximately one week [8].
Why is the pill dose 25 mg when the shot is 2.4 mg?
The milligram numbers are not comparable, and the label says so directly: Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis [1]. Swallowed peptide drugs face degradation from stomach acid and digestive enzymes and poor permeability across the gut lining [8], which is why oral semaglutide is co-formulated with the absorption enhancer SNAC [7][8].
For weight management specifically, the oral maintenance dose is 25 mg once daily, while the usual injectable maintenance dose is 2.4 mg once weekly [2]. The diabetes tablets have their own ladders: Rybelsus starts at 3 mg daily for days 1–30 (a dose the label states is not effective for glycemic control), moves to 7 mg for days 31–60, and can go to 14 mg from day 61 if more control is needed; Ozempic tablets follow the same pattern at 1.5 mg, then 4 mg, then 9 mg [1]. The full prescribing information contains separate instructions for switching between Rybelsus and Ozempic tablets and from Ozempic injection to the tablets [1].
How do the dosing schedules compare side by side?
For weight management, the two Wegovy forms titrate on different clocks. The injection starts at 0.25 mg once weekly for 4 weeks and titrates every 4 weeks toward the usual maintenance dose of 2.4 mg once weekly [2]. The tablet starts at 1.5 mg once daily for 30 days and titrates every 30 days toward the maintenance dose of 25 mg once daily [2].
| Wegovy injection | Wegovy tablets | |
|---|---|---|
| Starting dose | 0.25 mg once weekly × 4 weeks [2] | 1.5 mg once daily × 30 days [2] |
| Titration step | Every 4 weeks [2] | Every 30 days [2] |
| Usual maintenance | 2.4 mg once weekly [2] | 25 mg once daily [2] |
| Highest strength available | 7.2 mg single-dose pen (Wegovy HD) [2] | 25 mg tablet [2] |
| Food and timing rules | Any time of day, with or without meals [2] | Empty stomach, morning, up to 4 ounces of water, wait at least 30 minutes [2] |
For Ozempic injection, dosing starts at 0.25 mg once weekly, increases to 0.5 mg after 4 weeks, and can go to 1 mg or 2 mg once weekly if more glycemic control is needed; a missed dose may be given within 5 days [3]. In patients with diabetes, the Wegovy label says to monitor blood glucose before starting and during treatment [2].
Is the Wegovy pill as good as the shot?
There is no head-to-head trial in the published data. The pivotal trial for the pill, OASIS 4, compared oral semaglutide 25 mg against placebo — not against injectable semaglutide [5][6]. Novo Nordisk states that the weight loss achieved with the Wegovy pill is similar to that of injectable Wegovy 2.4 mg, but that is a company statement, not a direct comparison from the trial [4].
OASIS 4 was a 71-week, double-blind, randomized, placebo-controlled trial at 22 sites in four countries. It enrolled people without diabetes with a BMI of 30 or higher, or 27 or higher with at least one obesity-related complication, randomized 2:1 [5][6]. Of 307 participants, 205 took oral semaglutide 25 mg daily and 102 took placebo, both plus lifestyle intervention, over a 64-week treatment period [4][5][6].
At week 64, mean body weight changed by −13.6% in the oral semaglutide group versus −2.2% in the placebo group — an estimated treatment difference of −11.4 percentage points (95% CI −13.9 to −9.0; P<0.001) [5][6]. Significantly more participants on the pill reached reductions of at least 5%, 10%, 15%, and 20% of body weight (P<0.001 for all), and physical function quality-of-life scores improved versus placebo (P<0.001) [5][6]. Gastrointestinal adverse events occurred in 74.0% of the oral semaglutide group versus 42.2% of the placebo group [5][6].
Novo Nordisk separately reported a 16.6% mean weight loss figure — the trial-product estimand, meaning the estimated effect if everyone had adhered to treatment, not the primary all-participant result [4]. The company also reported that one in three participants achieved 20% or greater weight loss [4]. The trial was published in the New England Journal of Medicine on September 18, 2025, funded by Novo Nordisk (NCT05564117) [5]. The FDA approval, announced December 22, 2025, was based on the OASIS program plus the SELECT trial, supported by STEP program and PIONEER PLUS data [4]. The OASIS program consisted of four phase 3 trials of oral semaglutide 25 mg and 50 mg in about 1,300 adults [4].
What side effects and warnings apply to both forms?
Because the molecule is the same, the major warnings largely carry across products. Every semaglutide label carries a boxed warning that semaglutide causes thyroid C-cell tumors in rodents, that human relevance is undetermined, and that patients should be counseled about medullary thyroid carcinoma risk [1][2][3]. All the products are contraindicated in people with a personal or family history of MTC or Multiple Endocrine Neoplasia syndrome type 2, and after a serious hypersensitivity reaction to semaglutide or product excipients [1][2][3].
Listed warnings include acute pancreatitis, diabetic retinopathy complications, hypoglycemia when combined with insulin or insulin secretagogues, acute kidney injury from volume depletion, severe gastrointestinal reactions, hypersensitivity reactions, and acute gallbladder disease [1][3]. The tablets and Ozempic injection are not recommended in severe gastroparesis [1][3]. The most common adverse reactions reported in at least 5% of Ozempic injection patients are nausea, vomiting, diarrhea, abdominal pain, and constipation [3].
A few points are product-specific. Pulmonary aspiration during general anesthesia or deep sedation has been reported with GLP-1 receptor agonists; the Ozempic label instructs patients to tell providers about planned procedures [3]. Ozempic delays gastric emptying and may affect absorption of other oral drugs [3]. Because of semaglutide’s long washout, the Ozempic label says to discontinue it at least 2 months before a planned pregnancy [3]. Pens should never be shared between patients — the Ozempic label says so even if the needle is changed, and a June 2026 Wegovy label change added the same instruction for Wegovy FlexTouch [2][3]. A February 2026 Wegovy label change removed the Suicidal Behavior and Ideation section [2].
Which practical trade-offs matter when choosing pill or pen?
The pill means no needle, and research on oral semaglutide notes that oral administration may lead to earlier GLP-1 treatment initiation and may improve acceptance and adherence for some patients [8]. The cost is a daily routine: an empty stomach, water only, up to 4 ounces, and a wait of at least 30 minutes before anything else goes in [1][2][8].
The injection means a needle once a week, but no food or water rules and no timing restrictions — any time of day, with or without meals [2][3]. The highest injectable strength, 7.2 mg (Wegovy HD), has no tablet counterpart [2], and the injection is the only form covering adolescents aged 12 and older and the MASH liver indication [2].
Dosing decisions belong with a prescriber; the labels direct switching between products to specific instructions in the full prescribing information [1]. This page is informational only and is not medical advice.
When did the newest products become available?
The FDA approval of the Wegovy pill — once-daily oral semaglutide 25 mg — was announced by Novo Nordisk on December 22, 2025, making it the first oral GLP-1 receptor agonist approved for weight management [4]. Novo Nordisk expected a US launch in early January 2026 [4]. Oral semaglutide 25 mg for obesity was submitted to the EMA and other authorities in the second half of 2025, with the EMA decision pending at the time of the announcement [4].
The combined Rybelsus/Ozempic tablet label shows Indications updated 10/2025 and Dosage updated 12/2025 [1]; the Wegovy label shows Indications updated 08/2025 and 12/2025 and Dosage updated 08/2025, 12/2025, and 03/2026 [2].
Sources
- National Library of Medicine DailyMed. Ozempic and Rybelsus (oral semaglutide tablet) drug label.
- National Library of Medicine DailyMed. Wegovy (semaglutide injection, solution and tablet) drug label.
- National Library of Medicine DailyMed. Ozempic (semaglutide injection, solution) drug label.
- Novo Nordisk. Wegovy pill approved in the US as first oral GLP-1 for weight management. December 22, 2025.
- New England Journal of Medicine. Oral semaglutide at a dose of 25 mg in adults with overweight or obesity. 2025.
- Novo Nordisk Science Hub. Synopsis of oral semaglutide 25 mg in adults with overweight or obesity (OASIS 4). 2025.
- European Medicines Agency. Rybelsus (semaglutide) assessment report. January 30, 2020.
- Diabetes Therapy. Effect of various dosing conditions on the pharmacokinetics of oral semaglutide, a human glucagon-like peptide-1 analogue in a tablet formulation. June 2, 2021.
- PubMed Central. Relationship between oral semaglutide tablet erosion and pharmacokinetics: a pharmacoscintigraphic study.
- PR Newswire. Novo Nordisk’s Ozempic pill, the only FDA-approved oral peptide GLP-1 medication for adults with type 2 diabetes, soon to be available in the US. May 1, 2026.
- Drugs.com. Rybelsus (semaglutide) FDA approval history. April 23, 2026.
- Fierce Pharma. Novo’s Wegovy pill makes US debut, with starter dose launching at $149 per month for cash-paying patients. January 5, 2026.
- Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions. April 1, 2026.
- US Food and Drug Administration. FDA approves first new molecular entity under national priority voucher program.
- NovoCare Pharmacy. Wegovy (semaglutide) online pharmacy.
Frequently asked questions
Does the semaglutide pill work as well as the shot for weight loss?
There is no head-to-head trial. OASIS 4 compared the 25 mg daily pill against placebo, not against the injection, and found −13.6% versus −2.2% mean body-weight change at week 64. Novo Nordisk states the pill's weight loss is similar to injectable Wegovy 2.4 mg, but that is a company statement, not a direct trial comparison.
Why is the pill dose 25 mg when the shot is 2.4 mg?
The numbers are not comparable. The label states that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis. Swallowed peptide drugs face stomach acid, digestive enzymes, and poor gut permeability, which is why oral semaglutide is co-formulated with the absorption enhancer SNAC. Oral maintenance for weight management is 25 mg once daily versus 2.4 mg once weekly by injection.
What happens if you eat or drink coffee too soon after the tablet?
The label requires waiting at least 30 minutes after the tablet before food, beverages, or other oral medicines. In a food-effect trial, subjects who ate a meal 30 minutes before dosing had limited or no measurable semaglutide exposure, and exposure increased with longer post-dose fasting, especially from 15 to 30 minutes.
Can Rybelsus and Ozempic tablets be swapped at the same milligram?
No. The FDA label states that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis. They use different strength ladders — Rybelsus at 3, 7, and 14 mg; Ozempic tablets at 1.5, 4, and 9 mg — and the full prescribing information contains separate switching instructions.
Is the pill approved for teens or for MASH liver disease?
No. Wegovy tablets are approved for weight reduction and cardiovascular risk reduction in adults only. The injection covers patients aged 12 and older for weight reduction and holds the accelerated approval for noncirrhotic MASH with F2–F3 fibrosis, an indication the pill does not carry.
Do side effects differ between the tablet and the injection?
The core warnings are the same because the molecule is the same, including the thyroid C-cell boxed warning and contraindications for MTC history or MEN 2. In OASIS 4, gastrointestinal adverse events occurred in 74.0% of pill users versus 42.2% on placebo. Common injection reactions include nausea, vomiting, diarrhea, abdominal pain, and constipation.
How long does it take to reach the full dose on each form?
For weight management, the injection starts at 0.25 mg weekly for 4 weeks and titrates every 4 weeks toward 2.4 mg weekly maintenance; the tablet starts at 1.5 mg daily for 30 days and titrates every 30 days toward 25 mg daily maintenance. Diabetes tablets follow 30-day steps on their own schedules.
Can you take a semaglutide pill and an injection at the same time?
No. The Wegovy label states that concomitant use of Wegovy tablets or injection with other semaglutide-containing products, or with any other GLP-1 receptor agonist, is not recommended. Any change between products should follow the switching instructions in the full prescribing information, directed by a prescriber.
This article summarizes FDA labeling, published research and company information current as of September 14, 2026. It is not medical advice and does not replace a conversation with your own healthcare provider. How we research and verify.